Anthem Biosciences block deal: Portsmouth Applied sciences sells 30 lakh shares value Rs 250 crore
Based on BSE knowledge, Portsmouth Applied sciences LLC held 1,53,96,327 shares, representing a 2.73% stake in Anthem Biosciences, as of June 30, 2026. The 30 lakh shares offered symbolize roughly 19.49% of its holding as of that date.
Assuming no different adjustments in its shareholding since June 30, Portsmouth’s estimated holding after the transaction would stand at 1,23,96,327 shares. Its precise remaining holding would should be confirmed via up to date shareholding disclosures. The customer’s id was not instantly accessible.
Shares of Anthem Biosciences closed Friday’s buying and selling session at Rs 861.35, down 1.33% from the earlier shut of Rs 873. The inventory traded in a variety of Rs 833 to Rs 878.70 throughout the session. The block deal value was roughly 3.29% beneath the closing value.
The inventory has gained 34.80% to this point in 2026, in keeping with BSE analytics. At Friday’s closing value, the corporate’s market capitalisation stood at Rs 48,539.49 crore.
ALSO READ: Half of India’s MTF e-book is in smallcaps; Nithin Kamath flags liquidity dangers
Anthem Biosciences reported whole earnings of Rs 443.11 crore for the primary quarter of FY27, down 21.3% year-on-year from Rs 563.02 crore.The corporate’s revenue after tax declined 11.7% year-on-year to Rs 119.94 crore from Rs 135.79 crore within the corresponding quarter final 12 months. Revenue earlier than tax fell 22.4% to Rs 144.58 crore from Rs 186.25 crore, whereas earnings per share stood at Rs 2.11, in contrast with Rs 2.42 a 12 months earlier.
Anthem Biosciences IPO and itemizing efficiency
Anthem Biosciences shares made their D-Avenue debut on Monday, July 21, 2025, following the completion of its preliminary public providing (IPO), which comprised totally a suggestion on the market (OFS). Underneath the IPO, promoters and present shareholders provided as much as 5.96 crore fairness shares, valued at roughly Rs 3,395 crore on the subject value of Rs 570 per share.
The corporate’s shares listed at Rs 723.05 apiece, representing a premium of 26.85% over the IPO subject value.
At Friday’s closing value of Rs 861.35, Anthem Biosciences shares had been buying and selling at a premium of roughly 51.11% over the IPO subject value of Rs 570 per share.
Disclosure: This text has been written by Kumar Gaurav, who will not be a Sebi-registered Analysis Analyst or an Funding Adviser. Gaurav and their ‘relative(s)’ (as outlined beneath Part 2(77) of the Firms Act, 2013) don’t maintain any monetary curiosity within the corporations talked about on this article as of the date of publication. The views/suggestions talked about on this article, wherever relevant, are these of the respective Sebi-registered Analysis Analyst/brokerage and have been reproduced/reported with due attribution. They shouldn’t be construed because the views or suggestions of The Financial Instances Digital or the journalist. Readers are suggested to think about the unique analysis report and make their funding choices based mostly on their very own evaluation. Brokerage disclaimers right here
